ArticleThe Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
Restoring well-being: quality of life improvements following dolutegravir-based therapy after antiretroviral failure.
Article in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDolutegravir-based antiretroviral therapy has improved virologic outcomes in people living with HIV; however, its effects on Health-Related Quality of Life (HRQoL), particularly among individuals with prior antiretroviral failure, remain insufficiently characterized. We aimed to compare HRQoL in people living with HIV initiating dolutegravir-based regimens, with or without previous antiretroviral failure.
methodsThis multicenter study was conducted across 15 Brazilian HIV centers. Participants completed the RAND-36 questionnaire at baseline and after 12-months of dolutegravir-based therapy. HRQoL changes were assessed within groups and compared between groups using change scores over time.
resultsA total of 439 participants were included in the longitudinal analysis, of whom 373 had no prior therapeutic failure and 66 had previous antiretroviral failure. Among participants with prior failure, significant improvements were observed in role-emotional functioning (Δ = 17.17; p = 0.010), social functioning (Δ = 10.79; p = 0.008), and pain (Δ = 10.66; p = 0.024), whereas HRQoL remained stable among individuals switching therapy without prior failure. Between-group comparisons demonstrated significantly greater improvements in role-emotional functioning, social functioning, pain, and general health among individuals with prior therapeutic failure.
conclusionsSwitching to dolutegravir-based therapy was associated with stable HRQoL among individuals on suppressive regimens and with significant improvements among those with prior antiretroviral failure. These findings support the relevance of psychosocial and patient-reported outcomes in the evaluation of treatment response in people living with HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.